Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety
Version of Record online: 20 MAR 2007
Alimentary Pharmacology & Therapeutics
Volume 25, Issue 11, pages 1351–1361, June 2007
How to Cite
JOHANSON, J. F. and UENO, R. (2007), Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Alimentary Pharmacology & Therapeutics, 25: 1351–1361. doi: 10.1111/j.1365-2036.2007.03320.x
- Issue online: 20 MAR 2007
- Version of Record online: 20 MAR 2007
- Publication data Submitted 30 August 2006 First Decision 1 September 2006 Resubmitted 28 February 2007 Accepted 15 March 2007
- 1Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750–9., .Direct Link:
- 3Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936–71., .Direct Link:
- 4An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 3130–7., , , et al.Direct Link:
- 6Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 2004; 126(Suppl. 2): 298., , , et al.
- 8Multiple, escalating, oral-dose study to assess the safety, tolerance and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motility 2005; 17: 626..
- 14Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy. Am J Gastroenterol 2005; 100(Suppl. 9): S328–9., , , et al.